Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Document › Details

GenSight Biologics S.A.. (2/8/24). "Press Release: GenSight Biologics Announces Completion of a €5 million capital Increase with Sofinnova Partners, Invus, UPMC Enterprises and Heights Capital". Paris.

	Organisation	GenSight Biologics S.A. (Euronext: SIGHT)
	Organisation 2	Sofinnova Crossover I fund
	Group	Sofinnova (Group)
	Product	Lumevoq®
	Product 2	phase 3 study
	Index term	GenSight Biologics–SEVERAL: investment, 202402 capital increase €5m (€4.7m net) with 13.1m new shares at €0.38/share
	Person	Rodriguez, Laurence (GenSight Biologics 202312– CEO joined 5/21 as Head of Operations France before Sanofi Genzyme)
	Person 2	Tortet, Ivan (GenSight Biologics 202402 CFO)

Original document
accessed by [iito] on

Record changed: 2024-03-14

Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x200px

More documents for GenSight Biologics S.A. (Euronext: SIGHT)

[1] GenSight Biologics S.A.. (12/22/23). "Press Release: GenSight Biologics Appoints Laurence Rodriguez as Chief Executive Officer". Paris....
[2] GenSight Biologics S.A.. (11/21/23). "Press Release: GenSight Biologics Announces a Successful Offering for an Amount of approximately €4.7 Million". Paris....
[3] GenSight Biologics S.A.. (11/20/23). "Press Release: GenSight Biologics Announces Launch of an Offering for an Indicative Amount of €5 Million that Has Received Subscription Commitments from New and Existing Shareholders Totaling €4 Million". Paris....
[4] GenSight Biologics S.A.. (10/22/20). "Press Release: GenSight Biologics Successfully Raises €25 Million in an Oversubscribed Private Placement With US and European Institutional Investors". Paris....
[5] GenSight Biologics S.A.. (4/3/18). "Press Release: GenSight Biologics Announces Topline Results from REVERSE Phase III Clinical Trial of GS010 in Patients with Leber Hereditary Optic Neuropathy (LHON)". Paris....
[6] GenSight Biologics S.A.. (8/1/17). "Press Relase: GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy". Paris....
[7] GenSight Biologics S.A.. (7/28/17). "Press Relase: GenSight Biologics Reports Interim Financial Results for the First Half of 2017". Paris....
[8] GenSight Biologics S.A.. (6/23/17). "Press Release: GenSight Biologics Successfully Raises €22.5 Million from Leading Investors in the US and Europe [Not for distribution in Canada, Australia and Japan]". Paris....
[9] Reuters. (6/23/17). "News: BRIEF – Gensight Biologics Raises 22.5 Million Euros"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]